

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jenscare Scientific Co., Ltd.
寧波健世科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 9877)

VOLUNTARY ANNOUNCEMENT

**STRATEGIC COOPERATION AGREEMENT WITH
LIFETECH SCIENTIFIC CORPORATION**

This announcement is made by Jenscare Scientific Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and new product development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company announces that on February 6, 2023, the Company entered into a strategic cooperation agreement (the “**Strategic Cooperation Agreement**”) with LifeTech Scientific Corporation (“**LifeTech**”) in respect of potential cooperation including but not limited to business development, project investments and financing in mainland China and overseas.

COOPERATION FIELDS

Pursuant to the Strategic Cooperation Agreement, the Company and LifeTech shall explore a long-term and stable strategic cooperation relationship. In particular:

1. LifeTech shall assist the Company in the completion of clinical trials and product registrations in mainland China and overseas;
2. the parties shall cooperate strategically in the sales and marketing of products, including but not limited to in mainland China, Asia Pacific, Europe, North America and Latin America;
3. the parties shall cooperate and assist each other in the research and development of globally innovative products;

4. the parties shall cooperate in the development of a digitalized and automated production supply chain system in the long term; and
5. the parties shall share potential investments and merger and acquisition resources that will help the other party's product strategy, and promote the long term development of the parties.

If the parties agree to cooperate on specific projects in relation to the above areas in the future, the Company and LifeTech will enter into separate agreements which will set out the specific terms and conditions according to the principles under the Strategic Cooperation Agreement.

INFORMATION ON LIFETECH

LifeTech (together with its subsidiaries, the “**LifeTech Group**”), is listed on The Stock Exchange of Hong Kong Limited (stock code: 1302). LifeTech Group is a leading developer, manufacturer and marketer of advanced minimally invasive interventional medical devices for cardiovascular and peripheral vascular diseases and disorders. LifeTech Group currently has distributors in countries across Asia, Africa, North America, South America and Europe, with a sales network across more than 100 countries and/or regions.

INFORMATION ON THE COMPANY

The Company is a medical device company dedicated to the development of interventional products for the treatment of structural heart diseases. Established in 2011, it has developed a series of treatment solutions targeting different types of structural heart diseases, including tricuspid valve diseases, aortic valve diseases, mitral valve diseases and heart failure.

REASONS FOR AND BENEFITS OF THE STRATEGIC COOPERATION AGREEMENT

Having considered the overall strengths in the respective businesses and products, brand influence and ample resources of both parties to the Strategic Cooperation Agreement, the Company believes that the cooperation with LifeTech under the Strategic Cooperation Agreement will create synergy with the Group's businesses and international strategy and provide the Group with the chance to generate further revenue with an aim to enhance the profitability of the Group as a whole.

To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, save as being a shareholder of the Company holding approximately 1.35% of the total issued share capital of the Company as of the date of this announcement, Lifetech and its ultimate beneficial owners are third parties independent of the Company and its connected persons (as defined under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited).

SHAREHOLDERS OF THE COMPANY AND POTENTIAL INVESTORS ARE ADVISED TO EXERCISE DUE CARE WHEN DEALING IN THE SHARES OF THE COMPANY.

By order of the Board
Jenscare Scientific Co., Ltd.
Mr. LV Shiwen
Chairman and Executive Director

Hong Kong, February 6, 2023

As at the date of this announcement, the board of directors of the Company comprises Mr. LV Shiwen and Mr. PAN Fei, as executive Directors; Mr. TAN Ching, Mr. ZHENG Jiaqi, Ms. XIE Youpei and Mr. CHEN Xinxing, as non-executive Directors; and Dr. LIN Shoukang, Ms. DU Jiliu and Dr. MEI Lehe, as independent non-executive Directors.